[HTML] springer.com

[HTML][HTML] Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry

MV Huisman, C Teutsch, S Lu, HC Diener… - Clinical Research in …, 2022 - Springer
Background Prospectively collected, routine clinical practice-based data on antithrombotic
therapy in non-valvular atrial fibrillation (AF) patients are important for assessing real-world …
被引用次数：17 相关文章
[HTML] nih.gov

[HTML][HTML] Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry

MV Huisman, C Teutsch, S Lu, HC Diener… - Clinical Research in …, 2022 - ncbi.nlm.nih.gov
Background Prospectively collected, routine clinical practice-based data on antithrombotic
therapy in non-valvular atrial fibrillation (AF) patients are important for assessing real-world …

Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry

MV Huisman, C Teutsch, S Lu… - Clinical research in …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Prospectively collected, routine clinical practice-based data on antithrombotic
therapy in non-valvular atrial fibrillation (AF) patients are important for assessing real-world …

Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry.

MV Huisman, C Teutsch, S Lu, HC Diener… - Clinical Research in …, 2022 - europepmc.org
Background Prospectively collected, routine clinical practice-based data on antithrombotic
therapy in non-valvular atrial fibrillation (AF) patients are important for assessing real-world …

Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry

MV Huisman, C Teutsch, L Shihai… - Clinical Research in …, 2022 - search.proquest.com
Background Prospectively collected, routine clinical practice-based data on antithrombotic
therapy in non-valvular atrial fibrillation (AF) patients are important for assessing real-world …
[PDF] core.ac.uk

[PDF][PDF] Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA‑AF registry

MV Huisman, C Teutsch, S Lu, HC Diener… - Clinical Research in …, 2022 - core.ac.uk
Background Prospectively collected, routine clinical practice-based data on antithrombotic
therapy in non-valvular atrial fibrillation (AF) patients are important for assessing real-world …
[PDF] cardiorrenal.es

[PDF][PDF] Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA‑AF registry

MV Huisman, C Teutsch, S Lu, HC Diener, SJ Dubner… - 2022 - cardiorrenal.es
Background Prospectively collected, routine clinical practice-based data on antithrombotic
therapy in non-valvular atrial fibrillation (AF) patients are important for assessing real-world …

Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry

MV Huisman, C Teutsch, SH Lu… - Clinical …, 2022 - scholarlypublications …
Background: Prospectively collected, routine clinical practice-based data on antithrombotic
therapy in non-valvular atrial fibrillation (AF) patients are important for assessing real-world …

Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry.

MV Huisman, C Teutsch, S Lu, HC Diener… - Clinical Research in …, 2022 - europepmc.org
Background Prospectively collected, routine clinical practice-based data on antithrombotic
therapy in non-valvular atrial fibrillation (AF) patients are important for assessing real-world …